Ipsum Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 21-06-2024
- Paid Up Capital ₹ 4.70 M
as on 21-06-2024
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2021
- Revenue 4.07%
(FY 2017)
- Profit 9.17%
(FY 2017)
- Ebitda 1.42%
(FY 2017)
- Net Worth 9.88%
(FY 2017)
- Total Assets 36.78%
(FY 2017)
About Ipsum Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.70 M, as per Ministry of Corporate Affairs (MCA) records.
Narender Kalakuntla, Appala Shashikala, Shyamala Budda, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232TG2012PTC082077
- Company No.
082077
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2012
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ipsum Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narender Kalakuntla  | Director | 20-Jul-2012 | Current |
| Appala Shashikala | Director | 20-Jul-2012 | Current |
| Shyamala Budda | Director | 20-Jul-2012 | Current |
| Palla Aparna | Director | 20-Jul-2012 | Current |
| Abhishek Budda | Director | 20-Jul-2012 | Current |
Financial Performance of Ipsum Pharmaceuticals.
Ipsum Pharmaceuticals Private Limited, for the financial year ended 2017, experienced modest growth in revenue, with a 4.07% increase. The company also saw a slight improvement in profitability, with a 9.17% increase in profit. The company's net worth moved up by a moderate rise of 9.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ipsum Pharmaceuticals?
In 2017, Ipsum Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ipsum Pharmaceuticals?
Unlock and access historical data on people associated with Ipsum Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ipsum Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ipsum Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
